Q4 2024 · 13F-HR
Sanofi (SNY, SNYNF)holdings as filed
Filed 2025-02-14 · accession 0000950123-25-002465
$174.4M
Reported value
9
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G59665102 | MGTX | MeiraGTx Holdings plc | $74.3M | 42.6% | 12,197,737 | Common | SOLE |
| 670002401 | NVAX | Novavax | $55.3M | 31.7% | 6,880,481 | Common | SOLE |
| 45720N103 | INBX | Inhibrx Biosciences, Inc. | $17.8M | 10.2% | 1,157,926 | Common | SOLE |
| 032724106 | ANAB | AnaptysBio | $10.9M | 6.24% | 821,917 | Common | SOLE |
| 449585108 | 1K0 | IGM Biosciences | $8.8M | 5.04% | 1,438,975 | Common | SOLE |
| 28617K101 | ELDN | Eledon | $3.4M | 1.93% | 814,980 | Common | SOLE |
| N51517105 | 4PKB | LAVA Therapeutics N.V. | $1.8M | 1.05% | 1,919,455 | Common | SOLE |
| 45790W108 | — | Inozyme, Inc | $1.2M | 0.70% | 443,255 | Common | SOLE |
| 746964105 | QTTB | Q32 Bio Inc. | $839,646 | 0.48% | 244,083 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.